Eli Lilly and Company (NYSE:LLY) Shares Up 1% - Here's What Happened

Key Points

• Eli Lilly shares rose 1% to $1,257.26 in Friday trading, with volume below its daily average. The stock’s move came amid positive developments across its obesity, diabetes, vaccine and immunology pipelines.
• Lilly is collaborating with Chai Discovery on an RNA vaccine platform, while reports that its obesity treatments are gaining ground against Novo Nordisk support expectations for continued market-share growth and potential oral GLP-1 opportunities.
• Analyst sentiment remains bullish: multiple firms raised price targets, and MarketBeat lists a “Moderate Buy” consensus with a $1,292.18 target. Recent quarterly results also exceeded expectations, with adjusted EPS of $8.38 and revenue of $22.97 billion, up 47.7% year over year.

Eli Lilly and Company (NYSE:LLY - Get Free Report) was up 1% during trading on Friday . The company traded as high as $1,271.22 and last traded at $1,257.26. Approximately 2,494,212 shares changed hands during trading, a decline of 20% from the average daily volume of 3,101,136 shares. The stock had previously closed at $1,244.40.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly will collaborate with Boston-based biotech company Chai Discovery to develop an RNA vaccine platform. The partnership could expand Lilly’s long-term technology and vaccine pipeline, although financial details and near-term revenue implications were not disclosed. Lilly to work with Boston-based firm to develop RNA vaccine platform
• Positive Sentiment: Analyst enthusiasm remains strong, with Lilly identified as a leading candidate among stocks expected to deliver substantial earnings growth. This supports the bullish investment narrative surrounding its obesity and diabetes medicines. These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Tops Buy Point
• Positive Sentiment: Reports that Lilly’s obesity treatments are outpacing Novo Nordisk strengthen expectations for continued market-share gains. Investors are also watching the developing race in oral GLP-1 treatments, which could create another major growth opportunity beyond injectable medicines. Eli Lilly's obesity treatments outpace Novo Nordisk
• Positive Sentiment: Lilly completed a Phase 2b study of a treatment for hidradenitis suppurativa, adding depth to its immunology pipeline. The update is potentially supportive for the stock, though investors will need efficacy and regulatory data before assigning meaningful value. Eli Lilly Completes Mid-Stage Hidradenitis Suppurativa Trial, Adding Depth to Its Immunology Pipeline
• Neutral Sentiment: Several early- and late-stage study updates involving LY4178256, eloralintide, mirikizumab, lebrikizumab, dulaglutide, and other immunology programs indicate ongoing pipeline progress, but the announcements did not provide results likely to materially change near-term earnings expectations.
• Neutral Sentiment: Speculation that Lilly could announce a stock split reflects its high per-share price and strong appreciation. A split would improve trading accessibility but would not change the company’s intrinsic value or market capitalization. Stock Split Watch: Is Eli Lilly (LLY) Stock Next?

Analyst Upgrades and Downgrades

LLY has been the subject of several research analyst reports. Sanford C. Bernstein lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a research report on Tuesday, July 14th. Royal Bank Of Canada raised their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a research note on Wednesday, July 8th. Truist Financial lifted their price target on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 15th. Finally, Barclays increased their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an "overweight" rating in a report on Monday, May 4th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,292.18.

Eli Lilly and Company Stock Performance

The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The company has a market cap of $1.18 trillion, a price-to-earnings ratio of 42.19, a PEG ratio of 1.51 and a beta of 0.51. The firm's 50-day moving average price is $1,177.74 and its 200 day moving average price is $1,058.43.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is 23.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company's stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 over the last three months. Company insiders own 0.14% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of LLY. Willner & Heller LLC lifted its position in shares of Eli Lilly and Company by 1.0% in the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company's stock worth $1,100,000 after purchasing an additional 9 shares during the period. Aspiring Ventures LLC boosted its stake in shares of Eli Lilly and Company by 3.7% during the 2nd quarter. Aspiring Ventures LLC now owns 255 shares of the company's stock valued at $306,000 after purchasing an additional 9 shares in the last quarter. Wealthspan Partners LLC increased its position in shares of Eli Lilly and Company by 0.4% during the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company's stock valued at $2,543,000 after buying an additional 9 shares during the period. Navigoe LLC increased its position in shares of Eli Lilly and Company by 8.7% during the second quarter. Navigoe LLC now owns 113 shares of the company's stock valued at $135,000 after buying an additional 9 shares during the period. Finally, Atticus Wealth Management LLC raised its stake in Eli Lilly and Company by 0.5% in the second quarter. Atticus Wealth Management LLC now owns 1,664 shares of the company's stock worth $1,996,000 after buying an additional 9 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source